Published in J Natl Cancer Inst on November 15, 1995
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92
IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest (2002) 1.24
Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother (2010) 1.10
Anal melanoma. Clin Colon Rectal Surg (2006) 1.00
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
"First do no harm" and the importance of prediction in oncology. EPMA J (2010) 0.86
Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol (2015) 0.78
Shedding light on melanocyte pathobiology in vivo. Cancer Res (2012) 0.78
Re:Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1996) 0.78
Adjuvant therapy for melanoma: How should we respond to high-dose interferon? Br J Cancer (1998) 0.75
Targeting macrophage anti-tumor activity to suppress melanoma progression. Oncotarget (2017) 0.75
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol (2017) 0.75
Role of Type I and II Interferons in Colorectal Cancer and Melanoma. Front Immunol (2017) 0.75
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Changes in the epithelium of the cervix uteri. A study by the panel of pathologists engaged in the survey of carcinoma in situ carried out by the Royal College of Obstetricians and Gynaecologists. J Obstet Gynaecol Br Commonw (1966) 5.13
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
On estimating HLA/disease association with application to a study of aplastic anemia. Biometrics (1991) 4.81
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes. J Immunol (1968) 4.25
The histology and cytology of changes in the epithelium of the cervix uteri. J Clin Pathol (1969) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol (2000) 3.11
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
A centimeter here, a centimeter there: does it matter? J Am Acad Dermatol (1995) 2.67
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 2.66
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
New duplication-generating inversions in Neurospora. Can J Genet Cytol (1969) 2.30
Nucleotide sequence of 4.5 S ribonucleic acid of Novikoff hepatoma cell nuclei. J Biol Chem (1972) 2.30
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
A pericentric inversion in Neurospora, with unstable duplication progeny. Genetics (1967) 2.25
Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia (1999) 2.24
Methylation profiling in acute myeloid leukemia. Blood (2001) 2.22
Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. Nature (1991) 2.16
Use of lipid composition and metabolism to examine structure and activity of estuarine detrital microflora. Appl Environ Microbiol (1977) 2.12
Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest (1980) 2.03
Fluoropyrimidine biochemical modulation in colon cancer: pharmacology relevant in both the laboratory and the clinic. J Clin Oncol (1991) 2.02
The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore) (1979) 1.99
New markers and map sequences in Neurospora crassa, with a description of mapping by duplication coverage, and of multiple translocation stocks for testing linkage. Genetica (1969) 1.97
A non-capacitative pathway activated by arachidonic acid is the major Ca2+ entry mechanism in rat A7r5 smooth muscle cells stimulated with low concentrations of vasopressin. J Physiol (1999) 1.94
Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem (1986) 1.92
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Isolation and characterization of protein A24, a "histone-like" non-histone chromosomal protein. J Biol Chem (1975) 1.91
T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum (2002) 1.88
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res (2000) 1.81
Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer (1999) 1.79
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol (1995) 1.76
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
Evidence suggesting that a novel guanine nucleotide regulatory protein couples receptors to phospholipase C in exocrine pancreas. Biochem J (1986) 1.74
Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol (2001) 1.72
Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res (1983) 1.69
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology (1998) 1.69
Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem (1986) 1.68
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology (1991) 1.67
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol (2001) 1.66
Cooperative activation of IP3 receptors by sequential binding of IP3 and Ca2+ safeguards against spontaneous activity. Curr Biol (1997) 1.63
Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci (1993) 1.62
Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg (2001) 1.59
Effects of Ca2+ chelators on purified inositol 1,4,5-trisphosphate (InsP3) receptors and InsP3-stimulated Ca2+ mobilization. J Biol Chem (1993) 1.59
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med (1984) 1.57
Luminal Ca2+ increases the sensitivity of Ca2+ stores to inositol 1,4,5-trisphosphate. Mol Pharmacol (1992) 1.56
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol (1994) 1.56
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Cancer immunotherapy. Can Med Assoc J (1979) 1.54
Primary biliary cirrhosis in a patient with multiple sclerosis. Am J Gastroenterol (1989) 1.52
Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol (2001) 1.51
Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg (2001) 1.49
Differential regulation of types-1 and -3 inositol trisphosphate receptors by cytosolic Ca2+. Biochem J (1997) 1.49
All-or-nothing Ca2+ mobilization from the intracellular stores of single histamine-stimulated HeLa cells. J Physiol (1992) 1.49
Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85-04. Ann Surg Oncol (1995) 1.49
The management of dysplasia, carcinoma in situ and microcarcinoma of the cervix. J Obstet Gynaecol Br Commonw (1973) 1.48
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Two calcium-binding sites mediate the interconversion of liver inositol 1,4,5-trisphosphate receptors between three conformational states. Biochem J (1994) 1.47
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest (1981) 1.46
Vasopressin stimulation of Ca2+ mobilization, two bivalent cation entry pathways and Ca2+ efflux in A7r5 rat smooth muscle cells. J Physiol (1995) 1.45
The thiol reagent, thimerosal, evokes Ca2+ spikes in HeLa cells by sensitizing the inositol 1,4,5-trisphosphate receptor. J Biol Chem (1992) 1.44
Expression, characterization, and tissue distribution of a new cellular selenium-dependent glutathione peroxidase, GSHPx-GI. J Biol Chem (1993) 1.43
Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. Int J Tuberc Lung Dis (2004) 1.43
Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Quantal Ca2+ mobilization stimulated by inositol 1,4,5-trisphosphate in permeabilized hepatocytes. Biochem J (1991) 1.42
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42
Calcium and inositol trisphosphate receptors. J Membr Biol (1995) 1.41
Immunomorphological features of prognostic significance in Dukes' Class B colorectal carcinoma. Cancer Res (1977) 1.40
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst (1977) 1.40
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40
Epidermoid cyst of the scalp containing human papillomavirus. J Cutan Pathol (1993) 1.39
Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg (2001) 1.39
Lateral inhibition of inositol 1,4,5-trisphosphate receptors by cytosolic Ca(2+). Curr Biol (1999) 1.39
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med (1971) 1.38
Plasmalemmal pH-gradients in drug-sensitive and drug-resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic resonance spectroscopy. Biochem Pharmacol (1999) 1.38
Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol (1997) 1.36
Luminal Ca2+ promoting spontaneous Ca2+ release from inositol trisphosphate-sensitive stores in rat hepatocytes. J Physiol (1992) 1.35